SNSE — Sensei Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $10.69m
- -$29.81m
- 29
- 54
- 18
- 25
Annual income statement for Sensei Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.4 | 36.9 | 50.2 | 37.1 | 32.6 |
| Operating Profit | -19.4 | -36.9 | -50.2 | -37.1 | -32.6 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.1 | -36.8 | -48.6 | -34.1 | -30.2 |
| Net Income After Taxes | -20.1 | -36.8 | -48.6 | -34.1 | -30.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.1 | -36.8 | -48.6 | -34.1 | -30.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.2 | -36.8 | -48.6 | -34.1 | -30.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.66 | -1.35 | -1.58 | -1.2 | -1.16 |